Dr Marketa Skala, FRANZCR
Position:
- Director, Radiation Oncology, Royal Hobart Hospital
Biography:
Dr Marketa Skala is the director of the WP Holman clinic at the Royal Hobart Hospital. She trained at the St. Vincent's, Prince of Wales and Liverpool Hospitals in Sydney
Dr Skala’s research focuses on genito-urinary malignancy, with particular emphasis on prostate cancer and new technology. She completed a GU Fellowship at the Princess Margaret Hospital in Toronto, Canada and worked as a consultant in Halifax, Nova Scotia before taking up a position in Hobart, Tasmania.
She was the Chief investigator for an Australia-wide comparative study of Intensity Modulated Radiation Therapy (IMRT) prostate plans and was instrumental in formulating the Australia and New Zealand consensus guidelines for 3D conformal radiation therapy for prostate cancer in collaboration with the Faculty of Radiation Oncology Genito-urinary Group.
Dr Skala was the Principal investigator of late toxicity following high-dose, image-guided radiotherapy for prostate cancer at Princess Margaret Hospital, and its correlation with dosimetric parameters.
She spearheaded the development of IMRT for the treatment of prostate cancer at the Nova Scotia Cancer Centre, Canada and introduced image-guided radiotherapy to the WP Holman clinic in Hobart, Tasmania.
Dr Skala is the Chair of the Faculty of Radiation Oncology Genito-urinary Group, and the director of the Tasmanian Prostate Cancer Outcomes Research Database. She collaborates with the Menzies Centre on a number of translational research projects.
Best publications:
Australian and New Zealand 3D conformal radiation therapy consensus guidelines for prostate cancer. M.Skala, KH Tai, M.Berry, G. Duchesne, K. Gogna, K.H. Tai, S. Turner, A. Kneebone, A. Rolfo, A. Hayworth. Australasian Radiology 2004 Dec;48(4):493-501.
Patient-assessed late toxicity rates and principal component analysis after image guided radiation therapy for prostate cancer. M. Skala, T. Rosewall, L. Dawson, G. Lockwood, C. Thomas, J. Crook, P. Chung, P. Warde, C. Catton. International Journal of Radiation Oncology Biology and Physics 2007 July;68(3):690-698.
Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-guided Radiotherapy for Prostate Cancer. Vesprini D, Catton C, Jacks L, Lockwood G, Rosewall T, Bayley A, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Nichol A, Skala M, Warde P, Bristow RG. International Journal of Radiation Oncology Biology and Physics;2011 Nov
Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma. Hayden AJ, Martin JM, Kneebone AB, Lehman M, Wiltshire KL, Skala M, Christie D, Vial P, McDowall R, Tai KH; Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group. J Med Imaging Radiat Oncol. 2010 Dec;54(6):513-25.
Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Hindson BR, Turner SL, Millar JL, Foroudi F, Gogna NK, Skala M, Kneebone AB, Christie D, Lehman M, Wiltshire KL,Vial P, Tai KH; Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group. J Med Imaging Radiat Oncol. 2012 Feb;56(1):18-30.
Prostate cancer, Radiation Therapy, Translational research.
